摘要
目的探讨血管紧张素受体拮抗剂氯沙坦在糖尿病大鼠早期肾损伤中的保护作用及其机制。方法将36只实验动物随机分为正常对照组、糖尿病组及氯沙坦治疗组。链脲佐菌素(STZ)60 m g/kg制作糖尿病动物模型,检测各组大鼠的血糖、血肌酐、尿白蛋白、肾脏肥大指数的变化,免疫组织化学检测转化生长因子1β(TGF-1β)、蛋白激酶Cβ(PKCβ)的表达水平。结果治疗第8周末,氯沙坦治疗组较非治疗组白蛋白明显减少(P<0.01),肾脏肥大指数改善(P<0.05),免疫组织化学显示,糖尿病组大鼠肾小管TGF-1β和PK Cβ蛋白表达增多,氯沙坦治疗组TG F-1β和PKCβ蛋白表达均明显减少。结论氯沙坦对糖尿病早期肾脏病变有一定的保护作用,其机制可能是通过下调糖尿病大鼠TGF-1β和PKCβ的表达实现的。
Objective To observe the mechanism of the angiotensin Ⅱ receptor antagonist losartan for protecting the kidney from early injury in the diabetic rats. Methods The 36 experimental animal models were randomly divided into 3 groups：normal control group;diabetic group （injected with streptozotocin in a dosage of 60 mg/kg） ;diabetic group treated with losartan;plasma glucose,serum creatinine,urinary albumin,BUN and profile of kidney hypertrophy were observed after 8 weeks of treatment.Transforming growth factor-β1 （TGF-β1）,protein kinase C-β（PKC-β） expression was measured by immunohistochemistry. Results After 8 weeks,urinary albumin excretion （P〈0.01） and kidney hypertrophy index （P〈0.05） of losartan treated group were significantly lower than those in the diabetic group.The protein expression of TGF-β1 and PKC-β in losartan treated group was lower than those in the diabetic group. Conclusion Losartan may have kidney protective effect on diabetic rats,partly through down-regulating TGF-β1 and PKC-β expression.
出处
《中国药物与临床》
CAS
2005年第9期654-656,F0003,共4页
Chinese Remedies & Clinics
